Kin Foong Chan Net Worth

What's Kin Chan's mailing address?

Kin's mailing address filed with the SEC is C/O BIOPHARMX CORP, 1098 HAMILTON COURT, MENLO PARK, CA, 94025.

Insiders trading at BioPharmX

Over the last 10 years, insiders at BioPharmX have traded over $1,425,057 worth of BioPharmX stock and bought 7,392,667 units worth $2,162,100 . The most active insiders traders include Resources Inc Franklin, Capital Viii, Llc Vivo a Stephen Morlock. On average, BioPharmX executives and independent directors trade stock every 79 days with the average trade being worth of $308,564. The most recent stock trade was executed by Pharmaceuticals Llc Timber on 10 February 2020, trading 55,008 units of BPMX stock currently worth $550.

What does BioPharmX do?

BioPharmX Corp. is a specialty pharmaceutical company focused on developing prescription products utilizing its proprietary HyantX Topical Delivery System for dermatology indications. The HyantX delivery system is designed to stabilize and solubilize hydrophilic molecules in an anhydrous gel environment. The company was founded by James R. Pekarsky and Anja B. Krammer on August 30, 2010 and is headquartered in Campbell, CA.

BioPharmX executives and stock owners

BioPharmX executives and other stock owners filed with the SEC include:

• Lubor Gaal,
  Independent Director
• David Cohen,
  Independent Director
• Edward Sitar,
  Director
• Gianluca Pirozzi,
  Director
• Amir Tavakkol,
  Chief Scientific Officer
• Joyce Goto,
  Chief Accounting Officer
• Zachary Rome,
  Chief Operating Officer, Executive Vice President, Secretary, Director
• Joseph Lucchese,
  Chief Financial Officer, Executive Vice President
• John Koconis,
  Chief Executive Officer, Director
• Michael Derby,
  Executive Chairman of the Board
• Sciences Llc Tardi Med,
  10% owner
• Pharmaceuticals Llc Timber,
  10% owner
• David S Tierney,
  CEO
• Ronald Todd Plott,
  Director
• Stephen Morlock,
  Director
• Kin Foong Chan,
  EVP of R&D
• Anja B Krammer,
  President
• Michael Hubbard,
  Director
• Resources Inc Franklin,
  10% owner
• Capital Viii, Llc Vivo,
  10% owner
• Craig A. Barbarosh,
  Director
• Gregory David Kitchener,
  CFO
• Capital Fund Viii, L.P. Vivo,
  10% owner
• Charles Gregory Vontz,
  Director
• Steven Bosacki,
  Chief Operating Officer